Immune-based therapies for hepatocellular carcinoma

David J Pinato; Nadia Guerra; Petros Fessas; Ravindhi Murphy; Takashi Mineo; Francesco A Mauri; Sujit K Mukherjee; Mark Thursz; Ching Ngar Wong; Rohini Sharma; Lorenza Rimassa

doi:10.1038/s41388-020-1249-9

Immune-based therapies for hepatocellular carcinoma

David J Pinato, Nadia Guerra, Petros Fessas, Ravindhi Murphy, Takashi Mineo, Francesco A Mauri, Sujit K Mukherjee, Mark Thursz, Ching Ngar Wong, Rohini Sharma, Lorenza Rimassa

Istituto Clinico Humanitas

Research output: Contribution to journal › Review article › peer-review

Abstract

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

Original language	English
Pages (from-to)	3620-3637
Number of pages	18
Journal	Oncogene
Volume	39
Issue number	18
DOIs	https://doi.org/10.1038/s41388-020-1249-9
Publication status	Published - Apr 2020

Keywords

Cancer Vaccines/immunology
Carcinoma, Hepatocellular/immunology
Cell- and Tissue-Based Therapy/trends
Humans
Immunotherapy
Liver/immunology
Liver Neoplasms/immunology
Tumor Microenvironment/immunology

Access to Document

10.1038/s41388-020-1249-9

Fingerprint Dive into the research topics of 'Immune-based therapies for hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this

Immune-based therapies for hepatocellular carcinoma. / Pinato, David J; Guerra, Nadia; Fessas, Petros; Murphy, Ravindhi; Mineo, Takashi; Mauri, Francesco A; Mukherjee, Sujit K; Thursz, Mark; Wong, Ching Ngar; Sharma, Rohini; Rimassa, Lorenza.

In: Oncogene, Vol. 39, No. 18, 04.2020, p. 3620-3637.

Research output: Contribution to journal › Review article › peer-review

@article{7ea4751a3fed4aaa9fa013ae290ca780,

title = "Immune-based therapies for hepatocellular carcinoma",

abstract = "Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.",

keywords = "Cancer Vaccines/immunology, Carcinoma, Hepatocellular/immunology, Cell- and Tissue-Based Therapy/trends, Humans, Immunotherapy, Liver/immunology, Liver Neoplasms/immunology, Tumor Microenvironment/immunology",

author = "Pinato, {David J} and Nadia Guerra and Petros Fessas and Ravindhi Murphy and Takashi Mineo and Mauri, {Francesco A} and Mukherjee, {Sujit K} and Mark Thursz and Wong, {Ching Ngar} and Rohini Sharma and Lorenza Rimassa",

year = "2020",

month = apr,

doi = "10.1038/s41388-020-1249-9",

language = "English",

volume = "39",

pages = "3620--3637",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "18",

}

TY - JOUR

T1 - Immune-based therapies for hepatocellular carcinoma

AU - Pinato, David J

AU - Guerra, Nadia

AU - Fessas, Petros

AU - Murphy, Ravindhi

AU - Mineo, Takashi

AU - Mauri, Francesco A

AU - Mukherjee, Sujit K

AU - Thursz, Mark

AU - Wong, Ching Ngar

AU - Sharma, Rohini

AU - Rimassa, Lorenza

PY - 2020/4

Y1 - 2020/4

N2 - Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

AB - Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

KW - Cancer Vaccines/immunology

KW - Carcinoma, Hepatocellular/immunology

KW - Cell- and Tissue-Based Therapy/trends

KW - Humans

KW - Immunotherapy

KW - Liver/immunology

KW - Liver Neoplasms/immunology

KW - Tumor Microenvironment/immunology

U2 - 10.1038/s41388-020-1249-9

DO - 10.1038/s41388-020-1249-9

M3 - Review article

C2 - 32157213

VL - 39

SP - 3620

EP - 3637

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 18

ER -